Annexon, Inc. is advancing a next-generation platform of targeted immunotherapies for neuroinflammatory diseases.
Major milestones include potential approvals for GBS and pivotal Phase 3 data in GA.
2026 shows promise with significant progress in key programs like tanruprubart and vonaprument.
Tanruprubart MAA Filed
Potential to be the first targeted fast-acting therapy for Guillain-Barré Syndrome (GBS).
Vonaprument Phase 3 Data
Expected in the second half of 2026 for Dry AMD with Geographic Atrophy (GA).
ANX1502 Evaluation
Exploring the first oral C1 Inhibitor for autoimmune disease in 2026.
- Annexon's strong financial position secures operations beyond 2027.
- Vonaprument and tanruprubart have shown promising results in clinical trials, hinting at a shift in the standard of care for devastating diseases.
With a focus on innovation and patient benefits, Annexon aims to make a significant impact in neuroinflammatory diseases in 2026 and beyond.